Jean Enerson, Seattle Children’s board member and co-chair of the It Starts with Yes: The Campaign for Seattle Children’s, writes in a guest blog: “From covering the opening of the first T-cell immunotherapy trial when I was an anchor at KING 5 TV, to now seeing this therapy being tested in seven open clinical trials at Seattle Children’s and applied to a variety of cancers, I’ve been amazed to watch the enormous strides researchers have made in the field over a few short years.”
Gregg Bell asked Russell Wilson why he goes to Seattle Children’s each week. “Seattle Children’s does a tremendous job, first of all,” said Wilson. “I think it’s one of the best hospitals in the world, in how they treat their patients, and just the doctors that they have.
Endocyte’s value recently reached about $1.5 billion. The company’s primary technology focuses targeted therapeutics for personalized cancer treatment. Endocyte’s second major drug under development is a CAR-T cell immunotherapy.
Four years ago, KING 5 shared Milton Wright's story after he had completed immunotherapy treatment at Seattle Children's. Milton was the second patient to beat leukemia with T-cell immunotherapy, and after nearly 12 years of battling cancer, it's easy to understand why he would shy away from the medical setting.